Limited time75% off all plans
Get the app

Myelodysplastic syndromes

Myelodysplastic syndromes

Myelodysplastic syndromes

On this page

MDS Intro - The Failing Factory

  • Clonal hematopoietic stem cell disorders causing ineffective hematopoiesis (a dysfunctional bone marrow factory).
  • Leads to peripheral cytopenias (anemia, neutropenia, thrombocytopenia) despite a normo- or hypercellular marrow.
  • Hallmark is dysplasia (abnormal cell morphology) in one or more myeloid lineages.
  • Considered a pre-leukemic condition with risk of transformation to Acute Myeloid Leukemia (AML), defined by ≥20% blasts.

⭐ The central paradox of MDS is a hypercellular, "packed" bone marrow that yields peripheral cytopenias due to defective, apoptotic cells.

Pseudo-Pelger-Huët neutrophil and dyserythropoiesis in MDS

Pathophysiology - Corrupted Blueprints

  • Clonal mutation in a hematopoietic stem cell (HSC) is the primary insult.
  • Leads to ineffective hematopoiesis: marrow is hypercellular but cells are defective (dysplastic) and undergo apoptosis.
    • Results in peripheral blood cytopenias (anemia, neutropenia, thrombocytopenia).
    • Dysplastic changes visible in one or more cell lines (e.g., pseudo-Pelger-Huët cells, ring sideroblasts).
  • Represents a pre-malignant state with a high risk of transformation to Acute Myeloid Leukemia (AML).

MDS: Dysplastic megakaryocytes and erythroid precursors

MDS with isolated del(5q) is a unique subtype with a favorable prognosis, often presenting with thrombocytosis, and showing a robust response to lenalidomide therapy.

Diagnosis & Features - Spotting the Sabotage

  • Complete Blood Count (CBC):
    • Hallmark: Unexplained, persistent cytopenia(s), especially macrocytic anemia (↑ MCV).
  • Peripheral Blood Smear:
    • Shows dysplastic features in ≥1 cell line.
    • WBCs: Pseudo-Pelger-Huët cells (bilobed nuclei).
    • RBCs: Ovalomacrocytes.
    • Platelets: Giant or hypogranular platelets.
  • Bone Marrow Aspirate & Biopsy (Definitive Dx):
    • Hypercellular marrow despite peripheral cytopenias.
    • Dysplasia in ≥10% of cells in a lineage.
    • Key: Myeloblasts < 20%.

⭐ A blast count of ≥ 20% in the bone marrow or blood signifies transformation to Acute Myeloid Leukemia (AML).

  • Hallmark: Ineffective hematopoiesis → peripheral cytopenias despite a hypercellular or normocellular bone marrow.
  • Key Feature (Dyspoiesis): Abnormal maturation in ≥1 cell line.
    • Erythroid: Ring sideroblasts (>15% of precursors), megaloblastoid changes, nuclear budding.
    • Myeloid: Pseudo-Pelger-Huët cells (bilobed nuclei), hypogranulation.
    • Megakaryocytic: Micromegakaryocytes, "pawnball" nuclei (small, non-lobated).
  • Blasts: Bone marrow blasts are < 20%; reaching this threshold signifies transformation to AML.

Pseudo-Pelger-Huët cell and ring sideroblasts in MDS

MDS with isolated del(5q): Typically affects older women, presenting with macrocytic anemia, a normal or elevated platelet count, and carrying a favorable prognosis.

Prognosis & Treatment - Damage Control

  • Prognosis: Stratified by the IPSS-R score, which predicts survival and AML transformation risk. Key factors include marrow blast %, cytogenetics, and severity of cytopenias.
  • Supportive Care (Damage Control): The mainstay for lower-risk MDS, focused on managing marrow failure.
    • Anemia: RBC transfusions for symptoms; ESAs if serum EPO is <500 U/L.
    • Thrombocytopenia: Platelet transfusions for active bleeding.
    • Neutropenia: G-CSF for recurrent infections.
    • Iron Overload: Iron chelation for patients with chronic transfusion needs.

⭐ Isolated del(5q) syndrome is a unique entity with a favorable prognosis and high response rates to lenalidomide.

High‑Yield Points - ⚡ Biggest Takeaways

  • Clonal stem cell disorders in the elderly, leading to ineffective hematopoiesis and peripheral cytopenias.
  • Hallmark is dysplasia in one or more myeloid lineages, such as pseudo-Pelger-Huët cells and ring sideroblasts.
  • Bone marrow is paradoxically hypercellular despite low peripheral blood counts.
  • Patients often present with a macrocytic anemia (↑ MCV) resistant to standard therapies.
  • Carries a high risk of progression to Acute Myeloid Leukemia (AML).
  • The del(5q) syndrome subtype has a more favorable prognosis and often responds to lenalidomide.

Continue reading on Oncourse

Sign up for free to access the full lesson, plus unlimited questions, flashcards, AI-powered notes, and more.

CONTINUE READING — FREE

or get the app

Rezzy — Oncourse's AI Study Mate

Have doubts about this lesson?

Ask Rezzy, your AI Study Mate, to explain anything you didn't understand

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

START FOR FREE